Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMTNASDAQ:GYRENASDAQ:IMNMNASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$4.10-5.0%$3.76$2.24▼$28.93$189.72M2.81815,351 shs196,317 shsGYREGyre Therapeutics$8.14+4.4%$8.97$6.11▼$19.00$763.21M1.72128,869 shs66,030 shsIMNMImmunome$8.71+0.9%$8.65$5.15▼$16.81$757.86M1.92890,246 shs441,626 shsPHATPhathom Pharmaceuticals$8.77-1.6%$6.16$2.21▼$19.71$611.89M0.451.54 million shs499,121 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics-4.99%+0.61%+5.81%+47.83%-80.36%GYREGyre Therapeutics+4.36%+10.30%-0.97%+17.63%-30.55%IMNMImmunome+0.93%-0.91%-5.94%+46.88%-28.14%PHATPhathom Pharmaceuticals-1.63%-8.22%+77.07%+79.61%-14.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFDMT4D Molecular Therapeutics2.3255 of 5 stars3.32.00.00.02.31.70.6GYREGyre Therapeutics0.0832 of 5 stars0.02.00.00.00.60.80.0IMNMImmunome2.4932 of 5 stars3.52.00.00.02.62.50.0PHATPhathom Pharmaceuticals3.6083 of 5 stars4.51.00.00.01.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56621.75% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AIMNMImmunome 3.00Buy$23.33167.89% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5099.66% UpsideCurrent Analyst Ratings BreakdownLatest FDMT, IMNM, GYRE, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)6/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$40K4,743.03N/AN/A$11.05 per share0.37GYREGyre Therapeutics$105.76M7.22$0.21 per share39.49$1.05 per share7.75IMNMImmunome$9.04M83.83N/AN/A$2.27 per share3.84PHATPhathom Pharmaceuticals$55.25M11.07N/AN/A($3.71) per share-2.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)GYREGyre Therapeutics$12.09M$0.02407.20∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)IMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)Latest FDMT, IMNM, GYRE, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A12.3612.36GYREGyre TherapeuticsN/A3.603.19IMNMImmunomeN/A10.4910.49PHATPhathom PharmaceuticalsN/A3.583.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%GYREGyre Therapeutics23.99%IMNMImmunome44.58%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%GYREGyre Therapeutics10.00%IMNMImmunome8.60%PHATPhathom Pharmaceuticals23.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataIMNMImmunome4087.01 million79.53 millionOptionablePHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionableFDMT, IMNM, GYRE, and PHAT HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's WhyJuly 1 at 6:03 PM | marketbeat.comPhathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New MechanismJune 25, 2025 | seekingalpha.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - MorningstarJune 24, 2025 | morningstar.comMPhathom Pharmaceuticals, Inc. (PHAT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 23, 2025 | globenewswire.comPhathom Pharmaceuticals Appoints Cook as Chief Legal OfficerJune 23, 2025 | news.bloomberglaw.comNPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?June 23, 2025 | marketbeat.comPhathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate SecretaryJune 23, 2025 | globenewswire.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by BrokeragesJune 18, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?June 16, 2025 | marketbeat.comPhathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032June 16, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?June 12, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?June 11, 2025 | marketbeat.comTiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: BuyJune 10, 2025 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What HappenedJune 9, 2025 | marketbeat.comPhathom: Share Price Surge On Patent News May Not Stop The Rot For LongJune 9, 2025 | seekingalpha.comTraders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)June 9, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig HallumJune 9, 2025 | marketbeat.comWall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to TradeJune 9, 2025 | zacks.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC WainwrightJune 9, 2025 | marketbeat.comPhathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032June 8, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFDMT, IMNM, GYRE, and PHAT Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$4.10 -0.22 (-4.99%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$4.22 +0.13 (+3.17%) As of 07/3/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Gyre Therapeutics NASDAQ:GYRE$8.14 +0.34 (+4.36%) As of 07/3/2025 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Immunome NASDAQ:IMNM$8.71 +0.08 (+0.93%) Closing price 07/3/2025 03:23 PM EasternExtended Trading$8.85 +0.14 (+1.61%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Phathom Pharmaceuticals NASDAQ:PHAT$8.76 -0.15 (-1.63%) Closing price 07/3/2025 03:47 PM EasternExtended Trading$8.87 +0.10 (+1.20%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
